Nitrous Oxide Shows Promise as Rapid Relief for Treatment-Resistant Depression
A major meta-analysis published in eBioMedicine indicates that short-term treatment with nitrous oxide may offer significant benefits for individuals struggling with major depressive disorder (MDD), including those who haven’t responded to conventional antidepressants.
A growing body of research suggests that “repurposing” treatments from other medical fields could unlock new avenues for alleviating mood disorders. This latest study, led by researchers at the University of Birmingham, University of Oxford, and Birmingham and Solihull Mental Health NHS Foundation Trust, provides compelling evidence that clinically administered nitrous oxide (N2O) could be a valuable addition to the toolkit for treating depression.
Understanding Treatment-Resistant Depression
The research focuses on both MDD and treatment-resistant depression (TRD), a condition characterized by a lack of improvement after trials of at least two different antidepressants. According to previous research from the same team, TRD affects roughly 48% of patients in the UK who experience limited benefit from standard treatments. This highlights a critical unmet need for more effective interventions.
Rapid Symptom Reduction with Nitrous Oxide
The meta-analysis assessed data from seven clinical trials and four protocol papers from around the globe. Researchers discovered that a single treatment with inhaled nitrous oxide at a 50% concentration led to rapid and substantial reductions in depressive symptoms within 24 hours. However, these initial improvements were not sustained after one week.
Interestingly, repeated doses administered over several weeks resulted in more lasting improvements, suggesting that multiple treatment sessions are likely necessary to maintain clinical benefits. This finding is crucial for developing effective treatment protocols.
Mechanism of Action: A Similar Pathway to Ketamine?
The potential mechanism behind nitrous oxide’s antidepressant effects is thought to involve targeting glutamate receptors, mirroring the action of ketamine, another fast-acting antidepressant. “Improvements in mood can be observed soon after inhalation,” suggesting a similar neurological pathway is at play.
“Depression is a debilitating illness, made even more so by the fact that antidepressants make no meaningful difference for almost half of all patients diagnosed with it,” explained a Ph.D. researcher at the University of Birmingham and first author of the study. “This study brings together the best possible evidence indicating that nitrous oxide has the potential to provide swift and clinically significant short-term improvements in patients with severe depression.”
Evidence is Strong, But Further Research is Needed
While the meta-analysis revealed strong evidence for short-term mood improvements, researchers acknowledge the limitations of the existing studies. Variability in how depressive symptoms were measured and reported, as well as inconsistencies in assessment timing, were noted.
Further investigation is needed to pinpoint the optimal dosage, assess the long-term safety profile, and determine the best way to integrate nitrous oxide into existing treatment pathways.
The team also evaluated the safety and potential side effects of nitrous oxide. While some patients experienced mild side effects like nausea, dizziness, and headaches, these were generally transient and resolved without medical intervention. Higher concentrations (50%) were associated with a greater likelihood of these side effects, but no serious short-term safety concerns were identified. Long-term safety, however, requires further study.
“This is a significant milestone in understanding the potential of nitrous oxide as an added treatment option for patients with depression who have been failed by current treatments,” stated a senior author of the study and Honorary Consultant Psychiatrist at Birmingham and Solihull Mental Health Foundation Trust. “This population has often lost hope of recovery, making the results of this study particularly exciting.”
Future Directions: NHS Trial in the UK
The research was conducted by the Mental Health Mission Midlands Translational Center, which is dedicated to improving treatment options for treatment-resistant depression, particularly in underserved populations. The Center’s work aligns with the innovative treatments being delivered at the Birmingham Clinic for Advanced Mood Disorder Management (CALM), including ketamine and neuromodulation.
Building on this momentum, the team is preparing to launch the first NHS trial in the UK to evaluate the safety and acceptability of nitrous oxide as a treatment for major depression. The findings will inform how this treatment could be integrated into NHS care, potentially expanding options for patients who haven’t responded to conventional approaches.
More information: Nitrous oxide for the treatment of depression: A systematic review and meta-analysis, EBioMedicine (2025). DOI: 10.1016/j.ebiom.2025.106023
Provided by University of Birmingham.
Citation: Clinical use of nitrous oxide could help treat depression, major study shows (2025, November 30) retrieved 30 November 2025 from https://medicalxpress.com/news/2025-11-clinical-nitrous-oxide-depression-major.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
